- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | BioAtla reports promising early data for dual-CAB cancer therapy | 3 | Investing.com | ||
| 03.10. | BioAtla, Inc.: BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 | 5 | GlobeNewswire (USA) | ||
| 22.09. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | BioAtla: JMP bestätigt 'Market Perform'-Rating nach FDA-Zustimmung zum Phase-3-Design | 4 | Investing.com Deutsch | ||
| BIOATLA Aktie jetzt für 0€ handeln | |||||
| 09.09. | BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design | 2 | Investing.com | ||
| 08.09. | FDA aligns with BioAtla on phase 3 trial design for cancer drug | 6 | Investing.com | ||
| 13.08. | BioAtla stock downgraded by Citizens JMP on cash concerns | 2 | Investing.com | ||
| 08.08. | BioAtla im August 2025: Vielversprechende klinische Daten treffen auf finanziellen Gegenwind | 4 | Investing.com Deutsch | ||
| 08.08. | BioAtla August 2025 slides: promising clinical data amid financial headwinds | 2 | Investing.com | ||
| 07.08. | BioAtla GAAP EPS of -$0.32 misses by $0.03 | 2 | Seeking Alpha | ||
| 07.08. | BioAtla, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.08. | BioAtla, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | BioAtla, Inc.: BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 | 2 | GlobeNewswire (USA) | ||
| 03.07. | BioAtla, Inc.: BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European ... | 209 | GlobeNewswire (Europe) | Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients... ► Artikel lesen | |
| 20.06. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | BioAtla reports promising trial results for cancer drug | 4 | Investing.com | ||
| 16.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | BioAtla stock holds $1 target, JMP affirms Market Outperform | 2 | Investing.com | ||
| 27.03. | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | 252 | GlobeNewswire (Europe) | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| BB BIOTECH | 44,550 | +0,56 % | BB Biotech - Turning milestones into momentum | BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0%... ► Artikel lesen | |
| CUREVAC | 4,572 | -1,08 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 1,247 | -1,27 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| IBIO | 1,340 | -2,90 % | iBio, Inc. - 8-K, Current Report | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| MYRIAD GENETICS | 6,850 | -2,14 % | Exploring Myriad Genetics' Earnings Expectations | ||
| ABCELLERA BIOLOGICS | 4,819 | -0,12 % | Why Did AbCellera's Stock Jump Over 7% After Hours? | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,479 | +1,86 % | Coherus Oncology, Inc.: Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| OCULAR THERAPEUTIX | 10,235 | +1,19 % | Ocular Therapeutix stock price target raised to $20 from $14 at TD Cowen |
Das Unternehmen BIOATLA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,691 Euro und damit +0,09 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOATLA INC finden Sie auf Wallstreet Online.